Valuation: Incyte Corporation

Market Cap 2.36TCr 2.1TCr 1.95TCr 1.77TCr 3.32TCr 2,23900Cr 3.38TCr 23TCr 9.19TCr 1,17200Cr 8.87TCr 8.68TCr 3,73800Cr P/E 2026 *
61.4x
P/E 2027 * 16.3x
Enterprise Value 1.94TCr 1.72TCr 1.6TCr 1.45TCr 2.72TCr 1,83500Cr 2.77TCr 19TCr 7.53TCr 96TCr 7.27TCr 7.11TCr 3,06300Cr EV / Sales 2026 *
3.26x
EV / Sales 2027 * 2.83x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day+2.97%
1 week+7.36%
Current month-3.90%
1 month-6.94%
3 months+0.83%
6 months+20.32%
Current year+18.07%
1 week 112.02
Extreme 112.02
117
1 month 107.78
Extreme 107.7801
128.21
Current year 89.25
Extreme 89.25
132.6
1 year 84.02
Extreme 84.02
132.6
3 years 50.27
Extreme 50.27
132.6
5 years 50.27
Extreme 50.27
132.6
10 years 50.27
Extreme 50.27
153.15
Manager TitleAgeSince
Chief Executive Officer 58 26/06/2025
Director of Finance/CFO 57 04/05/2026
President 62 05/06/2023
Director TitleAgeSince
Chairman 59 26/06/2025
Director/Board Member 72 20/01/2015
Director/Board Member 64 20/01/2015
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Tax

EVP, Head of Incyte Intl

-463 0.0002%
30/09/26 Other

Director

0 0% -
30/09/26
FBS Associates LLC
OtherCompany 0 0% -
Change 5-day change 1-year change 3-year change Capi.($)
+2.97%+7.36%+35.33%+111.53% 2.36TCr
+3.49%+10.04%+58.68%+119.56% 1,14400Cr
+2.19%+4.32%+33.88%+69.52% 63TCr
+2.26%+5.37%+24.57%+97.69% 51TCr
+0.12%+5.04%+38.75%+64.01% 38TCr
+3.25%+4.45%+71.80%+44.44% 37TCr
+0.13%+3.23%+21.10%+49.85% 29TCr
-0.04%+2.54%+1.11%+24.87% 26TCr
+3.29%+6.32%+44.71%+57.43% 24TCr
+2.25%+5.81%+27.13%+101.17% 19TCr
Average +0.22%+6.42%+35.71%+74.01% 40.32TCr
Weighted average by Cap. -0.16%+6.91%+40.91%+81.24%

Financials

2026 *2027 *
Net sales 593.67Cr 528.42Cr 489.74Cr 443.78Cr 834.03Cr 56TCr 847.99Cr 5.88TCr 2.31TCr 29TCr 2.23TCr 2.18TCr 94TCr 624.53Cr 555.89Cr 515.2Cr 466.85Cr 877.39Cr 59TCr 892.08Cr 6.18TCr 2.43TCr 31TCr 2.34TCr 2.29TCr 99TCr
Net income 39Cr 35Cr 33Cr 29Cr 55Cr 3.74TCr 56Cr 390.42Cr 153.38Cr 1.96TCr 147.95Cr 144.88Cr 6.24TCr 148.28Cr 131.98Cr 122.32Cr 110.84Cr 208.31Cr 14TCr 211.8Cr 1.47TCr 576.59Cr 7.35TCr 556.19Cr 544.65Cr 23TCr
Net Debt -426.87Cr -379.96Cr -352.14Cr -319.1Cr -599.71Cr -40TCr -609.75Cr -4.23TCr -1.66TCr -21TCr -1.6TCr -1.57TCr -68TCr -594.61Cr -529.27Cr -490.52Cr -444.49Cr -835.36Cr -56TCr -849.35Cr -5.89TCr -2.31TCr -29TCr -2.23TCr -2.18TCr -94TCr
Projected Income Statement - Annual - Incyte Corporation
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
20/26/20 $116.62 +2.97% 13,41,784
19/26/19 $113.25 +0.16% 11,90,058
16/26/16 $113.07 -0.18% 15,80,667
15/26/15 $113.27 +1.52% 19,40,494
14/26/14 $111.57 +2.72% 18,70,089
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Incyte Corporation
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
116.62USD
Average target price
129.50USD
Spread / Average Target
+11.05%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Incyte Corporation
  1. Stock Market
  2. Stocks
  3. INCY Stock